Skip to main content

IDWeek 2023 Main banner

Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Ziqiang Chen, PhD

Merck & Co., Inc.

Poster(s):

(1741) A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Vaxelis™ or Hexyon™ (V419-016)

Friday, October 13, 2023
12:15 PM – 1:30 PM US ET